Mekinist

Chemical Nametrametinib
Dosage FormTablet (oral; 0.5 mg, 2 mg)
Drug ClassKinase inhibitors
SystemSkin, Respiratory, Blood, Endocrine
CompanyNovartis
Approval Year2013

Indication

  • For the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.
  • Indicated in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
  • Indicated in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
  • Indicated in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
  • Indicated in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
Last updated on 6/21/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Mekinist (trametinib) Prescribing Information.2022Novartis Pharmaceuticals Corporation, East Hanover, NJ
Document TitleYearSource
Acceptability of drugs in the treatment of unresectable/metastatic BRAF V600-mutant melanoma: a systematic review and network meta-analysis.2022Frontiers in Oncology
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.2021BMC Cancer
Adjuvant therapy of high-risk (stages IIC-IV) malignant melanoma in the post interferon-alpha era: a systematic review and meta-analysis.2021Frontiers in Oncology
Economic evaluation of systemic treatments for advanced melanoma: a systematic review.2020Value Health
Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: a systematic review and network meta-analysis. 2020Dermatologic Therapy
Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: a systematic review and network meta-analysis. 2019Dermatologic Therapy
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. 2019European Journal of Cancer
Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review.2019Cancers
Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. 2019Cancer Treatment Reviews
How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. 2018European Journal of Cancer
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.2017BMJ Open
Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. 2017Current Medical Research and Opinion